{"id":742300,"date":"2013-10-23T06:30:00","date_gmt":"2013-10-23T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/"},"modified":"2023-03-22T00:04:33","modified_gmt":"2023-03-22T04:04:33","slug":"zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/","title":{"rendered":"ZOSTAVAX\u00ae (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that ZOSTAVAX\u00ae (Zoster Vaccine Live), the company&#8217;s<br \/>\n      vaccine to help prevent shingles, received the Prix Galien USA 2013<br \/>\n      Award for Best Biotechnology Product.\n    <\/p>\n<p>\n      \u201cMerck is honored to have been chosen as a recipient of this prestigious<br \/>\n      award,\u201d said Dr. Roger M. Perlmutter, president, Merck Research<br \/>\n      Laboratories. \u201cThis achievement is a testament to the remarkable<br \/>\n      contributions of everyone at Merck who played a role in helping to bring<br \/>\n      ZOSTAVAX to market.\u201d\n    <\/p>\n<p>\n      The <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.prix-galien-usa.com%2F&#038;esheet=50734779&#038;newsitemid=20131023005542&#038;lan=en-US&#038;anchor=Prix+Galien+Award&#038;index=1&#038;md5=05a469be3cf333c512f2c3983c94568f\" rel=\"nofollow\">Prix<br \/>\n      Galien Award<\/a> recognizes the pharmaceutical industry&#8217;s outstanding<br \/>\n      achievement in the development of new medicines. An internationally<br \/>\n      recognized award, the Prix Galien was founded in France in 1969 by<br \/>\n      French pharmacist Roland Mehl and is considered the highest accolade for<br \/>\n      pharmaceutical research and development.\n    <\/p>\n<p>\n      This latest award for ZOSTAVAX is Merck&#8217;s sixth Prix Galien USA award in<br \/>\n      seven years. The company was previously recognized for <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Fcorporate-news%2Fvictrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-a&#038;esheet=50734779&#038;newsitemid=20131023005542&#038;lan=en-US&#038;anchor=VICTRELIS+%282012%29&#038;index=2&#038;md5=1b53991953266e5ec6d0c7e51810a46a\" rel=\"nofollow\">VICTRELIS<br \/>\n      (2012)<\/a>, ROTATEQ (2010), ISENTRESS (2008), and JANUVIA and GARDASIL<br \/>\n      (2007). In total, around the world, Merck has won the Prix Galien more<br \/>\n      than 30 times, making Merck one of the two most-awarded companies of all<br \/>\n      time.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50734779&#038;newsitemid=20131023005542&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=3&#038;md5=4eb0d9f20269b1df15709bdb113cd8c5\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50734779&#038;newsitemid=20131023005542&#038;lan=en-US&#038;anchor=Twitter&#038;index=4&#038;md5=ac30d2e222428af6c90128b4ee296370\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50734779&#038;newsitemid=20131023005542&#038;lan=en-US&#038;anchor=Facebook&#038;index=5&#038;md5=29f55100ef523b432444bbd0afba65d4\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50734779&#038;newsitemid=20131023005542&#038;lan=en-US&#038;anchor=YouTube&#038;index=6&#038;md5=265d7d3bd8d9a5f9c07666d62063534d\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50734779&#038;newsitemid=20131023005542&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=7&#038;md5=0e3708151912e93aea282231b3146fc2\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20131023005542r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Media:<br \/>Merck<br \/>Caroline Lappetito, (267) 305-7639     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that ZOSTAVAX\u00ae (Zoster Vaccine Live), the company&#8217;s vaccine to help prevent shingles, received the Prix Galien USA 2013 Award for Best Biotechnology Product. \u201cMerck is honored to have been chosen as a recipient of this prestigious award,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThis achievement is a testament to the remarkable contributions of everyone at Merck who played a role in helping to bring ZOSTAVAX to market.\u201d The Prix Galien Award recognizes the pharmaceutical industry&#8217;s outstanding achievement in the development of new medicines. An internationally recognized award, the Prix Galien was founded in France in 1969 by French pharmacist Roland Mehl and is considered the highest accolade for pharmaceutical research and development. This latest award for ZOSTAVAX is Merck&#8217;s sixth Prix Galien USA award in seven years. The company was previously recognized for<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-742300","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ZOSTAVAX\u00ae (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZOSTAVAX\u00ae (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that ZOSTAVAX\u00ae (Zoster Vaccine Live), the company&#039;s vaccine to help prevent shingles, received the Prix Galien USA 2013 Award for Best Biotechnology Product. \u201cMerck is honored to have been chosen as a recipient of this prestigious award,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThis achievement is a testament to the remarkable contributions of everyone at Merck who played a role in helping to bring ZOSTAVAX to market.\u201d The Prix Galien Award recognizes the pharmaceutical industry&#039;s outstanding achievement in the development of new medicines. An internationally recognized award, the Prix Galien was founded in France in 1969 by French pharmacist Roland Mehl and is considered the highest accolade for pharmaceutical research and development. This latest award for ZOSTAVAX is Merck&#039;s sixth Prix Galien USA award in seven years. The company was previously recognized for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:33+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131023005542r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\\\/\",\"name\":\"ZOSTAVAX\u00ae (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131023005542r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2013-10-23T06:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131023005542r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131023005542r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ZOSTAVAX\u00ae (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ZOSTAVAX\u00ae (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/","og_locale":"en_US","og_type":"article","og_title":"ZOSTAVAX\u00ae (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that ZOSTAVAX\u00ae (Zoster Vaccine Live), the company's vaccine to help prevent shingles, received the Prix Galien USA 2013 Award for Best Biotechnology Product. \u201cMerck is honored to have been chosen as a recipient of this prestigious award,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThis achievement is a testament to the remarkable contributions of everyone at Merck who played a role in helping to bring ZOSTAVAX to market.\u201d The Prix Galien Award recognizes the pharmaceutical industry's outstanding achievement in the development of new medicines. An internationally recognized award, the Prix Galien was founded in France in 1969 by French pharmacist Roland Mehl and is considered the highest accolade for pharmaceutical research and development. This latest award for ZOSTAVAX is Merck's sixth Prix Galien USA award in seven years. The company was previously recognized for","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:33+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131023005542r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/","name":"ZOSTAVAX\u00ae (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131023005542r1&sid=hq1sf1&distro=nx","datePublished":"2013-10-23T06:30:00+00:00","dateModified":"2023-03-22T04:04:33+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131023005542r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131023005542r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/zostavax-zoster-vaccine-live-awarded-prix-galien-usa-2013-best-biotechnology-product\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"ZOSTAVAX\u00ae (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d9179f73-9a86-4eb8-99a4-a894f645961c","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742300\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742300"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}